JOCOAT Safety and Tolerability Clinical Trial GLAD-04

NCT ID: NCT07081815

Last Updated: 2025-09-02

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-30
• Study Completion Date: 2026-12-31

Brief Summary

This study will assess the safety and efficacy of a new liquid anti-adhesion device, JOCOAT(TM) APN-3003 in patients undergoing knee anterior cruciate ligament reconstruction (ACLR) surgery.

This is a single-center, prospective study. Safety and clinical outcomes will be compared with historical controls from enrolled study site patients from NCT03935750 (STABILITY 2) which has evaluated outcomes following ACL rupture in young athletes.

A maximum of 24 patients aged 15-25 years undergoing primary anatomic ACLR with quadriceps tendon (QT) graft following a standardized surgical treatment algorithm will be enrolled. All patients will receive JOCOAT(TM) APN-3003 at the end of their surgery.

Conditions

Surgical Adhesions

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

JOCOAT(TM) APN-3003

Intra-articular injection

Group Type: EXPERIMENTAL

JOCOAT(TM) APN-3003

Intervention Type: DEVICE

10 mL of JOCOAT(TM) APN-3003 is applied at the end of surgery

Interventions

JOCOAT(TM) APN-3003

10 mL of JOCOAT(TM) APN-3003 is applied at the end of surgery

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Understand and be able to follow the requirements of the protocol including personally signing and dating an REB approved Informed Consent Form prior to undergoing any protocol related procedures
• Subjects aged 15 to 25 years with an ACL-deficient knee undergoing primary ACLR
• Subjects with skeletal maturity (i.e. closed epiphyseal growth plates on standard knee radiographs)
• At least two of the following factors that are associated with a high risk of graft failure:

1. participate in a competitive pivoting sport (defined as sports that include cutting and pivoting activities such as basketball, American football, soccer, lacrosse, volleyball, tennis/squash, handball, downhill skiing etc);

2. have a pivot shift of grade 2 or greater;

3. have generalized ligamentous laxity (Beighton score of >= 4) and/or genu recurvatum > 10 degrees

• Biological females have a negative pregnancy test within 4 days of initial surgery
• Is willing, able and likely to fully comply with clinical trial procedures and restrictions including follow-ups

• Patient undergoes primary anatomic anterior cruciate ligament reconstruction surgery with quadriceps tendon (QT) graft

Exclusion Criteria

• Simultaneous bilateral ACLR
• Previous ACLR on either knee
• Less than one year from contralateral knee or contralateral/ipsilateral hip/ankle surgery
• Prior arthrotomy in the study knee
• Active infection anywhere or previous infection in the study knee
• History of peri-articular fracture in study knee
• > 3 degrees of asymmetric varus or valgus
• The patient has debilitating knee pain that would preclude the use of QT tissue as a graft
• The patient has a significant quad tendonitis that would preclude the use of QT tissue as a graft
• Known or suspected allergy to brown seaweed, seaweed-based materials such as fucoidan, food allergies and/or presence of any allergy related dietary restrictions unless deemed by the investigator as "Not Clinically Significant"
• Known or suspected allergy to fucose, galactose, sulfur, sulfate, sulfite, or any sugar-based polymer or polysaccharides containing these
• Known hypersensitivity to sodium lactate or sulfur-containing compounds
• Any other severe allergic conditions or previous reactions (e.g., anaphylactic reactions, angioedema)
• Severe metabolic acidosis or alkalosis
• Have insulin dependent diabetes, severe diabetes and/or poorly controlled diabetes mellitus
• Any general medical or surgical condition that would preclude a standard knee ACLR
• Inflammatory arthropathy
• Breast feeding
• Have a medical condition that, in the opinion of the investigator would interfere with the evaluation of the safety or efficacy of the investigational product
• Have received any investigational products that, in the opinion of the investigator, would interfere with the evaluation of the safety or efficacy of the investigational product
• Have clinically relevant hemochromatosis, hepatic, renal, autoimmune, lymphatic, hematological or coagulation disorders
• Family history of blood or coagulation disorders
• History of heparin-induced thrombocytopenia (HIT) or known sensitivity to heparin-like products

• Pre-existing arthrofibrosis in the knee
• Partial ACL rupture (defined as one bundle ACL tear requiring reconstruction/ augmentation of the torn bundle with no surgery required for the intact bundle) where ACLR is not performed
• Multiple ligament injury (two or more ligaments requiring surgery)
• Symptomatic articular cartilage defect requiring treatment other than debridement
• Articular cartilage lesion that requires any other surgical treatment apart from debridement
• Under anesthetic, this patient has a symmetrical or grade 1 pivot shift AND has a Beighton score <4 AND <10 degrees hyperextension

• Minimum Eligible Age: 15 Years
• Maximum Eligible Age: 25 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ARC Medical Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

ARCMD-GLAD-04

Identifier Type: -

Identifier Source: org_study_id